Jeffrey B. Mirviss - 21 Feb 2023 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role
EVP&Pres, Periph Intervent
Signature
/s/ Susan Thompson, Attorney-in-Fact
Issuer symbol
BSX
Transactions as of
21 Feb 2023
Net transactions value
-$320,240
Form type
4
Filing time
22 Feb 2023, 15:55:44 UTC
Previous filing
21 Feb 2023
Next filing
31 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSX Common Stock Options Exercise $0 +2,804 +3% $0.000000 95,411 21 Feb 2023 Direct F1
transaction BSX Common Stock Tax liability $59,128 -1,279 -1.3% $46.23 94,132 21 Feb 2023 Direct
transaction BSX Common Stock Sale $107,138 -2,313 -2.5% $46.32 91,819 21 Feb 2023 Direct F2
transaction BSX Common Stock Sale $153,974 -3,340 -3.6% $46.10 88,479 22 Feb 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Deferred Stock Units Options Exercise $0 -2,804 -100% $0.000000* 0 21 Feb 2023 Common Stock 2,804 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2 The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.
F3 Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.